Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48
healthy volunteers, aged 18 to 65 years.
The study will include up to 6 planned cohorts; each cohort will comprise 8 subjects.
Each subject will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and
will undergo scheduled assessments over a period of 13 weeks.
The main aim of the study is to assess the safety and tolerability of single doses of
MEDI1341 in Healthy Volunteers.